The pursuit of better AD therapies is in progress, with about 20 drugs currently in phase 3 clinical trials targeting various aspects of AD pathology including the amyloid cascade, the modulation of neurotransmitter receptors, synaptic plasticity, proteostasis, tau tangles, inflammation, metabolism, and circadian rhythm [5]. Here, MAPT is linked to Alzheimer disease.